High Performance Medical Plastics Market Projected To Record A Robust Cagr Of 7.8% By 2026- Exclusive Report By Marketsandmarkets™

By Author: Jack Martin
Total Articles: 250
Comment this article

The global high performance medical plastics market size is projected to grow from USD 851 million in 2021 to USD 1,242 million by 2026, at a CAGR of 7.8% during the forecast period 2021 to 2026. The growing use of advanced medical technologies, such as 3D printed implants and customized devices is one of the major factor propelling the growth of the high performance medical plastics market.

Get PDF Brochure for Research Insights at: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=146073142

By type, the FP segment accounted for the largest market share in 2020. Various types of FP such as Polytetrafluoroethylene (PTFE), Polyvinylidene Fluoride (PVDF), and Fluorinated Ethylene Propylene (FEP) are widely used in various applications. Surgical equipment, such as handles and grips for instrumentation, sizing trials for knee and hip replacement, fixation devices, endoscopic housings, and eyepieces, are manufactured using high performance fluoropolymers, owing to their high chemical resistance. These FPs have greater thermal stability and temperature resistance property and are, thus, widely used to manufacture ...
... parts for X-ray and Magnetic Resonance Imaging (MRI) devices. The larger share of the FP segment can be attributed to the increase in demand for PTFE and FEP in medical applications such as components of medical devices, surgical instruments, and therapeutic systems, among others.

Solvay SA (Belgium), SABIC (UAE), Mitsubishi Chemical Corporation (Japan), Evonik Industries AG (Germany), Arkema SA (France), Ensinger (Germany), Victrex PLC (UK), Rochling SE & Co. AG (Germany), Raumedic AG (Germany), The Chemours Company (US), DuPont (US), Saint-Gobain Performance Plastics (France), Celanese Corporation (US), Trelleborg (Sweden) and Tekni-Plex (US) are some of the leading players operating in the high performance medical plastics market. These players have adopted the strategies of acquisitions and partnerships to enhance their position in the market.

Solvay SA is the largest company in the global high performance medical plastics market. High performance plastics are a part of the materials business segment of the company. Solvay SA operates through 428 subsidiaries in 64 countries of Europe, North America, Latin America, and Asia-Pacific. The company has 119 operational facilities worldwide. As a global leader in materials, chemicals, and solutions, Solvay brings advancements in planes, cars, batteries, smart and medical devices, and water and air treatment, to solve critical industrial, social, and environmental challenges. Solvay SA, in December 2020 entered into a partnership with PrinterPrezz (US) to develop 3D printing Selective Laser Sintering (SLS) solutions for implants and other medical devices using high performance polymers.

Get the Latest Version of the Report and ahead from Your Competitors: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=146073142

Another important player in the high-performance medical plastics market is Evonik Industries AG. The company has vast experience in manufacturing high-performance medical plastics and a broad product portfolio, huge production capacity, and sales, logistics, and technical service network. Evonik has a dedicated section for medical plastic division and products like VESTAKEEP, VESTAMID and TRAGOMID care have application in dental applications, body implants and medical devices. Evonik is one of the world leaders in specialty chemicals. Evonik goes far beyond chemistry to create innovative, profitable, and sustainable solutions for customers. The company has done major acquisitions and joint ventures with companies like Durect Corporation and Wynka Silicon for increasing its high-performance medical plastics market.

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their pain points around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 Micro Quadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.